8,054 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Wick Capital Partners LLC

Wick Capital Partners LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 8,054 shares of the company’s stock, valued at approximately $1,142,000.

Other hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC raised its position in shares of Neurocrine Biosciences by 83.7% during the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after purchasing an additional 1,263,633 shares during the period. Norges Bank bought a new stake in Neurocrine Biosciences during the 4th quarter valued at $162,664,000. UBS Group AG boosted its position in Neurocrine Biosciences by 169.8% during the 4th quarter. UBS Group AG now owns 983,528 shares of the company’s stock worth $139,494,000 after acquiring an additional 618,956 shares during the period. Zurich Insurance Group Ltd FI acquired a new position in Neurocrine Biosciences during the 4th quarter worth $65,162,000. Finally, Two Sigma Investments LP bought a new position in shares of Neurocrine Biosciences in the third quarter worth $48,791,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on NBIX. Truist Financial raised their price target on Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Canaccord Genuity Group increased their target price on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Weiss Ratings raised shares of Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, June 3rd. Finally, Morgan Stanley boosted their price target on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $187.52.

Neurocrine Biosciences Trading Down 0.4%

Shares of NASDAQ NBIX opened at $158.29 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $169.57. The firm has a 50-day moving average of $148.02 and a two-hundred day moving average of $140.72. The company has a market capitalization of $15.92 billion, a price-to-earnings ratio of 24.39, a PEG ratio of 1.19 and a beta of 0.40.

Insiders Place Their Bets

In related news, Director Leslie V. Norwalk sold 1,250 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $168.06, for a total transaction of $210,075.00. Following the completion of the sale, the director directly owned 2,838 shares in the company, valued at approximately $476,954.28. This trade represents a 30.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the completion of the transaction, the insider owned 25,846 shares in the company, valued at approximately $4,141,821.50. This trade represents a 29.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 355,234 shares of company stock worth $55,330,060. Company insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.